Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $108 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $108.
December 20, 2023 | 3:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reaffirmed an Overweight rating on Axsome Therapeutics with a $108 price target, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests a strong conviction in the company's potential. This could instill confidence among investors and positively influence the stock price in the short term. The maintenance of a high price target further emphasizes the analyst's bullish stance on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100